Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21647729 | 1.00 | SLC6A3 (0.38) | SLC6A3KMT2AMEN1EP300CREBBP | |
| SCHEMBL23440867 | 0.88 | SLC6A3 (0.39) | SLC6A3PTGER4 | |
| SCHEMBL23440869 | 0.88 | SLC6A3 (0.39) | SLC6A3PTGER4 | |
| SCHEMBL21647850 | 0.87 | FKBP1A (0.34) | SLC6A3KMT2AMEN1PTGER4 | |
| SCHEMBL29191833 | 0.87 | FKBP1A (0.34) | SLC6A3KMT2AMEN1PTGER4 | |
| SCHEMBL29483738 | 0.87 | FKBP1A (0.34) | SLC6A3KMT2AMEN1PTGER4 | |
| SCHEMBL29191834 | 0.86 | SLC6A3 (0.35) | SLC6A3KMT2AACEPTGER4ATM | |
| SCHEMBL21647801 | 0.81 | KIF11 (0.36) | SLC6A3PTGER4 | |
| SCHEMBL21647800 | 0.81 | KIF11 (0.36) | SLC6A3PTGER4 | |
| SCHEMBL30409321 | 0.81 | KIF11 (0.36) | SLC6A3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188023-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| US-12258308-B2 | Benzene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-25 | — | — | US | disclosed |
| US-20220089532-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258308-B2 | Benzene derivative | PMP22, TMBIM6, MYT1 | SLC6A3 2855/4885KMT2A 2511/4885MEN1 2716/4885 |
| US-20250188023-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | SLC6A3 2807/4885KMT2A 2388/4885MEN1 2705/4885 |
| US-20220089532-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | SLC6A3 2855/4885KMT2A 2511/4885MEN1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.